CIBC Asset Management Inc grew its stake in Becton Dickinson and Co (NYSE:BDX) by 4.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 53,233 shares of the medical instruments supplier’s stock after acquiring an additional 2,294 shares during the period. CIBC Asset Management Inc’s holdings in Becton Dickinson and were worth $13,294,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in BDX. Harvest Group Wealth Management LLC purchased a new stake in shares of Becton Dickinson and in the 1st quarter valued at approximately $25,000. Oregon Public Employees Retirement Fund increased its position in shares of Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 6,545,502 shares during the last quarter. Pinnacle Financial Partners Inc. purchased a new stake in shares of Becton Dickinson and in the 1st quarter valued at approximately $29,000. RPG Investment Advisory LLC purchased a new stake in shares of Becton Dickinson and in the 1st quarter valued at approximately $32,000. Finally, Nalls Sherbakoff Group LLC purchased a new stake in shares of Becton Dickinson and in the 4th quarter valued at approximately $34,000. 85.24% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Ribo Alberto Mas sold 4,808 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $1,226,184.24. Following the completion of the transaction, the executive vice president now owns 22,476 shares in the company, valued at approximately $5,732,054.28. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Betty D. Larson sold 1,700 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $224.97, for a total transaction of $382,449.00. Following the completion of the transaction, the executive vice president now owns 11,493 shares of the company’s stock, valued at approximately $2,585,580.21. The disclosure for this sale can be found here. In the last 90 days, insiders sold 31,384 shares of company stock valued at $7,901,023. Company insiders own 0.12% of the company’s stock.
Shares of Becton Dickinson and stock opened at $222.84 on Thursday. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $60.36 billion, a PE ratio of 20.24, a P/E/G ratio of 1.68 and a beta of 1.16.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The business had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter in the prior year, the business posted $2.65 EPS. The company’s revenue for the quarter was down .6% on a year-over-year basis. As a group, research analysts expect that Becton Dickinson and Co will post 11.69 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 7th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.38%. The ex-dividend date of this dividend is Thursday, June 6th. Becton Dickinson and’s payout ratio is 27.97%.
A number of equities research analysts have commented on the stock. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Barclays increased their price objective on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research report on Monday, April 15th. Raymond James dropped their price objective on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research report on Tuesday, March 19th. Finally, TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $255.31.
COPYRIGHT VIOLATION WARNING: “Becton Dickinson and Co (BDX) Shares Bought by CIBC Asset Management Inc” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2019/05/16/becton-dickinson-and-co-bdx-shares-bought-by-cibc-asset-management-inc.html.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: Asset Allocation and Your Retirement
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.